Updated on 26 October 2026
The company Samsung Biologics Co. Ltd announced that 87.59% of the outstanding shares and voting rights, respectively, of PolyPeptide Group AG would be attributable to the bidder.
The settlement of the offer is still subject to the entry of further offer conditions. The shares underlying the affected contracts are changed to the tendered line effective 27 October 2026. The tendered line will serve as the underlying of the affected contracts until further notice.
Accordingly, the ISIN of the above-mentioned contracts will change as specified in the following table.
Product code old/new | ISIN of the underlying instrument old | ISIN of the underlying instrument new | Product-ISIN old | Product-ISIN new |
| | | | |
On 20 July 2026 the company Samsung Biologics Co. Ltd announced its proposal to acquire PolyPeptide Group AG via a takeover offer to the shareholders of PolyPeptide Group AG at a price of CHF 44.31 per share.
More information about this transaction is available on the companies` websites.
This information describes the potential effects this transaction will have on the above-mentioned contracts.